HBK Sorce Advisory LLC Buys Shares of 7,047 Thermo Fisher Scientific Inc. $TMO

Key Points

• HBK Sorce Advisory initiated a position in Thermo Fisher Scientific, purchasing 7,047 shares valued at approximately $4.07 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, exceeding analyst estimates, while revenue increased 10.5% year over year. The company projects fiscal 2026 EPS of $24.93–$25.33.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $619.41. The company also declared a quarterly dividend of $0.47 per share, yielding about 0.3%.

HBK Sorce Advisory LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 7,047 shares of the medical research company's stock, valued at approximately $4,072,000.

Other hedge funds have also made changes to their positions in the company. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $7,505,000. Boston Trust Walden Corp lifted its holdings in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock valued at $25,480,000 after acquiring an additional 3,873 shares during the last quarter. Hudson Value Partners LLC boosted its position in shares of Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock valued at $8,349,000 after purchasing an additional 3,317 shares in the last quarter. Xponance LLC grew its stake in shares of Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock worth $34,358,000 after purchasing an additional 4,436 shares during the last quarter. Finally, Sandro Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $2,089,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.3%

Thermo Fisher Scientific stock opened at $586.62 on Tuesday. The company has a 50 day moving average price of $531.72 and a 200 day moving average price of $508.48. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The firm has a market capitalization of $216.90 billion, a price-to-earnings ratio of 31.56, a P/E/G ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 52,053 shares of company stock worth $30,643,589. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TMO shares. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a report on Friday, May 8th. Royal Bank Of Canada increased their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Jefferies Financial Group reaffirmed a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, Barclays increased their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source